4//SEC Filing
Liu Ye 4
Accession 0001562180-23-004632
CIK 0001314102other
Filed
May 30, 8:00 PM ET
Accepted
May 31, 5:22 PM ET
Size
5.4 KB
Accession
0001562180-23-004632
Insider Transaction Report
Form 4
Liu Ye
Director
Transactions
- Sale
Common Stock, $0.001 par value
2023-05-30$6.00/sh−1$6→ 3,010,721 total(indirect: Ocumension Therapeutics)
Footnotes (2)
- [F1]Sale of one share to test new broker
- [F2]The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001840407
Filing Metadata
- Form type
- 4
- Filed
- May 30, 8:00 PM ET
- Accepted
- May 31, 5:22 PM ET
- Size
- 5.4 KB